A stricter interpretation of anti-kickback rules
Yet another kickback scheme allegation hit Teva (TEVA) yesterday, sending its stock down over 10%. - New about this umpteenth lawsuit, however, was that it related to Copaxone, i.e. Teva's own drug, so this time Teva could not point to its unfortunate Actavis acquisition as the origin of all evil.
Unfortunately, there can be little doubt that Teva actually did what the lawsuit alleges.
First of all, the described scheme is similar to many out there: Teva is accused of having set up foundations to avoid co-pay